梅花生物(600873.SH):2023年擬使用短時閒置自有資金購買理財產品餘額不超40億元
格隆匯3月6日丨梅花生物(600873.SH)公佈,為提高公司自有資金使用效率,公司擬以短時閒置自有資金購買理財產品。2023年公司(含控股子公司)擬使用短時閒置自有資金購買理財產品餘額不超過40億元,購買期限以一年內的短期品種為主,品種包括但不限於商業銀行、商業銀行理財子公司、證券公司、基金公司、信託公司、資產管理公司、投資公司等合法合規機構發行的各類理財產品及份額,購買股票及國債、國開債、農發債等利率債,購買發行主體評級或債項評級已取得國內AA+級及以上的各類信用債以及監管機構認定的其他合規產品。預期上述產品的綜合年化收益率高於同期銀行活期存款利率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.